Clinical Trials Directory

Trials / Unknown

UnknownNCT06253429

Alpha-lipoic Acid in Diabetic Nephropathy

Oxidative Stress in Children and Adolescents With Diabetic Nephropathy and the Role of Adjuvant Alpha-lipoic Acid as an Antioxidant

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Ain Shams University · Academic / Other
Sex
All
Age
6 Years – 18 Years
Healthy volunteers
Not accepted

Summary

Endothelial dysfunction in diabetes is a central event in the pathogenesis of different microangioapthic changes. Nephropathy in patients with type 1 diabetes is a severe microvascular complication.

Detailed description

Better understanding of the pathogenesis of microvascular complications in type 1 diabetes have paved the way for novel therapeutic targets and possible adjuvant therapeutic modalities. Oxidative stress is considered a common and important factor that links hyperglycemia with the vascular complications in diabetes, including of diabetic nephropathy (DN). Alpha lipoic acid (ALA), or thioctacid, is an antioxidant compound which serve as a cofactor for mitochondrial respiratory enzymes. ALA can scavenge free radicals, activate antioxidant systems, and also affect inflammatory markers. It also has unique characteristic. ALA can play as a reduction for oxidized forms of components with antioxidant properties and neutralize reactive oxygen species. Thus, it called as antioxidant of antioxidants

Conditions

Interventions

TypeNameDescription
DRUGThioctic Acid 333 MG Oral CapsuleAntioxidant compound which serve as a cofactor for mitochondrial respiratory enzymes
DRUGCaptopril 25Mg TabOral angiotensin-converting enzyme inhibitors

Timeline

Start date
2023-01-01
Primary completion
2024-01-31
Completion
2024-02-01
First posted
2024-02-12
Last updated
2024-02-12

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT06253429. Inclusion in this directory is not an endorsement.